BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism
Science Advances · 21.06.2024 · 10 (25)
DOI: 10.1126/sciadv.adj8650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 21.06.2024. Verfasst von Huizhi Sun und 18 weiteren Autor:innen. Beteiligte Einrichtung: Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Pre…. Hauptthemen laut MEDLINE: Tryptophan, Drug Resistance, Neoplasm, Neoplastic Stem Cells, Pancreatic Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Pancreatic adenocarcinoma is the fourth leading cause of malignancy-related deaths, with rapid development of drug resistance driven by pancreatic cancer stem cells. However, the mechanisms sustaining stemness and chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC) remain unclear. Here, we demonstrate that Bicaudal C homolog 1 (BICC1), an RNA binding protein regulating numerous cytoplasmic mRNAs, facilitates chemoresistance and stemness in PDAC. Mechanistically, BICC1 activated tryptophan catabolism in PDAC by up-regulating indoleamine 2,3-dioxygenase-1 (IDO1) expression, a tryptophan-catabolizing enzyme. Increased levels of tryptophan metabolites contribute to NAD + synthesis and oxidative phosphorylation, leading to a stem cell-like phenotype. Blocking BICC1/IDO1/tryptophan metabolism signaling greatly improves the gemcitabine (GEM) efficacy in several PDAC models with high BICC1 level. These findings indicate that BICC1 is a critical tryptophan metabolism regulator that drives the stemness and chemoresistance of PDAC and thus a potential target for combinatorial therapeutic strategy against chemoresistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Key Laboratory of Digestive Cancer, Tianj…
- Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, PA, USA.
- Tianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, School of Medicine, Nankai University, Tianjin, P. R. China.
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
ORCID-Profile: Huizhi Sun, Hui Li, Yuqi Guan, Tiansuo Zhao, Yukuan Feng, Hongwei Wang, Shengyu Yang, Yi Shi, Jing Liu, Antao Chang, Chongbiao Huang, Jihui Hao
Förderung
- NCI NIH HHS
Zitieren
APA
Sun, H., Li, H., Guan, Y., Yuan, Y., Xu, C., Fu, D., Xie, P., Li, J., Zhao, T., Wang, X., Feng, Y., Wang, H., Gao, S., Yang, S., Shi, Y., Liu, J., Chang, A., Huang, C., & Hao, J. (2024). BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Science Advances, 10(25). https://doi.org/10.1126/sciadv.adj8650
Vancouver
Sun H, Li H, Guan Y, Yuan Y, Xu C, Fu D, et al. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Science Advances. 2024;10(25). doi:10.1126/sciadv.adj8650
BibTeX
@article{Sun2024,
author = {Sun, Huizhi and Li, Hui and Guan, Yuqi and Yuan, Yudong and Xu, Chao and Fu, Danqi and Xie, Peng and Li, Jianming and Zhao, Tiansuo and Wang, Xiuchao and Feng, Yukuan and Wang, Hongwei and Gao, Song and Yang, Shengyu and Shi, Yi and Liu, Jing and Chang, Antao and Huang, Chongbiao and Hao, Jihui},
title = {BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {25},
doi = {10.1126/sciadv.adj8650}
}
EUVIMED